NEW YORK--(BUSINESS WIRE)--May 1, 2019--
bio (Nasdaq:ISEE) today announced that it will report its
first quarter 2019 financial and operating results on Wednesday, May 8,
2019. Following the announcement, IVERIC bio’s management team will host
a live conference call and webcast at 8:00 a.m. Eastern Time to discuss
the Company’s financial results and provide a general business update.
To participate in this conference call, dial 888-224-1005 (USA) or
323-794-2551 (International), passcode 9765307. A live, listen-only
audio webcast of the conference call can be accessed on the Investors
section of the IVERIC bio website at www.ivericbio.com.
A replay will be available approximately two hours following the live
call for two weeks. The replay number is 888-203-1112 (USA Toll Free),
About IVERIC bio
IVERIC bio is a biotechnology company with a focus on the discovery and
development of novel gene therapy solutions to treat orphan inherited
retinal diseases with unmet medical needs. Vision is Our Mission. For
more information on the Company's gene therapy and other programs,
please visit www.ivericbio.com.
Any statements in this press release about IVERIC bio’s future
expectations, plans and prospects constitute forward-looking statements
for purposes of the safe harbor provisions under the Private Securities
Litigation Reform Act of 1995. Actual results may differ materially from
those indicated by such forward-looking statements as a result of
various important factors. Any forward-looking statements represent
IVERIC bio’s views only as of the date of this press release. IVERIC bio
anticipates that subsequent events and developments will cause its views
to change. While IVERIC bio may elect to update these forward-looking
statements at some point in the future, IVERIC bio specifically
disclaims any obligation to do so.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190501005023/en/
Source: IVERIC bio
President, Investor Relations and Corporate Communications
SmithSolve LLC on behalf of IVERIC bio